source
- Northwest Biotherapeutics' brain cancer therapy faces 931-day delay in UK approvalNorthwest Biotherapeutics, a public biotech developing a brain cancer treatment, filed a marketing application with the UK Medicines and Healthcare products Regulatory Agency (MHRA) in late Decembe…
- New OpenEvidence study shows it outperforms general-purpose LLMs in health-tech researchA recent study funded by OpenEvidence compared its platform to general-purpose large language models (LLMs) in health technology research and concluded that OpenEvidence delivered more accurate and…